Low serum testosterone and mortality in older men. by Gail A Laughlin et al.
Low Serum Testosterone and Mortality in Older Men
Gail A. Laughlin, Elizabeth Barrett-Connor, and Jaclyn Bergstrom
Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093
Context: Declining testosterone levels in elderly men are thought to underlie many of the symp-
toms and diseases of aging; however, studies demonstrating associations of low testosterone with
clinical outcomes are few.
Objective: The objective of the study was to examine the association of endogenous testosterone
levels with mortality in older community-dwelling men.
Design, Setting, and Participants: This was a prospective, population-based study of 794 men, aged
50–91 (median 73.6) yr who had serum testosterone measurements at baseline (1984–1987) and
were followed for mortality through July 2004.
Main Outcome Measure: All-cause mortality by serum testosterone level was measured.
Results: During an average 11.8-yr follow-up, 538 deaths occurred. Men whose total testosterone
levels were in the lowest quartile (241 ng/dl) were 40% [hazards ratio (HR) 1.40; 95% confidence
interval (CI) 1.14–1.71] more likely to die than those with higher levels, independent of age,
adiposity, and lifestyle. Additional adjustment for health status markers, lipids, lipoproteins, blood
pressure, glycemia, adipocytokines, and estradiol levels had minimal effect on results. The low
testosterone-mortality association was also independent of the metabolic syndrome, diabetes, and
prevalent cardiovascular disease but was attenuated by adjustment for IL-6 and C-reactive protein.
In cause-specific analyses, low testosterone predicted increased risk of cardiovascular (HR 1.38; 95%
CI 1.02–1.85) and respiratory disease (HR 2.29; 95% CI 1.25–4.20) mortality but was not significantly
related to cancer death (HR 1.34; 95% CI 0.89–2.00). Results were similar for bioavailable
testosterone.
Conclusions: Testosterone insufficiency in older men is associated with increased risk of death over
the following 20 yr, independent of multiple risk factors and several preexisting health conditions.
(J Clin Endocrinol Metab 93: 68–75, 2008)
In contrast to the dramatic fall in estrogen levels at the time ofmenopause in women, testosterone concentrations in men
decline gradually with aging. Many adverse aspects of male aging
have been attributed to the decrease in endogenous testosterone,
stimulating a surge of interest in testosterone therapy for middle-
aged and older men. Testosterone sales in the United States in-
creased 20-fold during the 1990s (1). However, solid evidence
linking testosterone insufficiency to health-related outcomes in
older men is just beginning to emerge, and even less information
is available on testosterone and mortality.
Approximately 30% of men 60 yr old and older are estimated
to have low testosterone (2), which is often accompanied by
undesirable signs and symptoms such as low bone and muscle
mass; increased fat mass (especially central adiposity); low en-
ergy; and impaired physical, sexual, and cognitive function. That
these complaints have clinical consequences is supported by pro-
spective cohort studies showing that men with low testosterone
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are at increased risk of falls (3); hip fracture (if estradiol is also
low) (4); anemia (5); type 2 diabetes (6); depressive illness (7);
and, in some studies, Alzheimer’s disease (8, 9). Whether these
associations translate into reduced survival is less clear.
A small study of men living in a geriatric rehabilitation unit
found that those with low testosterone had increased 6-month
mortality, compared with men of the same age, and medical
morbidity whose testosterone levels were normal (10). Low tes-
tosterone levels were also associated with increased mortality
over the following 8 yr in a larger retrospective study of male
veterans who attended a hospital clinic (11). However, the men
in these studies were in poor health, and acute illness is known
to reduce testosterone production (12). Two recent population-
based studies of comparatively healthy men with longer fol-
low-up (15–16 yr) did not find an association of testosterone
with survival (13, 14). However, the men in these studies were
relatively young at baseline (mean age early 50s) and the survival
effects of testosterone insufficiency may only be apparent late in
the lifespan.
We report here the association of serum testosterone with all
cause and cause-specific mortality among 794 community-
dwelling older men from the Rancho Bernardo Study whose av-
erage age was 72 yr at baseline and who were followed for 20 yr.
Subjects and Methods
Study population
The Rancho Bernardo Study is a population-based study of healthy
aging in Caucasian residents of a Southern California community. Be-
tween 1984 and 1987, 82% (n  1060) of surviving community-dwell-
ing older male participants attended a research clinic visit. During this
visit, information regarding medical history, medication use, physical
activity (exercise 3 times per week, yes/no), alcohol consumption
(1drinks/day vs. less or none), and current smoking (yes/no) was ob-
tained using standard questionnaires. Current medication use was val-
idated by examination of pills and prescriptions brought to the clinic for
that purpose. The study protocol was approved by the Institutional Re-
view Board of the University of California, San Diego. All participants
gave written informed consent.
Of the 1060 men who attended the 1984–1987 clinic visit, 885 (84%)
had sufficient stored sera for measurement of testosterone and other sex
hormones. Twenty men were excluded for testosterone levels suggestive
of surgical or biochemical castration (90 ng/dl), 53 decedents because
death certificates have not been obtained, and 18 for loss to follow-up.
The remaining 794 men (75% of the original cohort) are the subject of
this report. Compared with those without hormone assays, men with
testosterone measurements were slightly younger and less likely to have
diabetes but did not differ in terms of weight, body mass index (BMI),
waist girth, lifestyle characteristics, or known heart disease.
Clinical measurements
Height, weight, and waist and hip girth were measured in the clinic
with participants wearing light clothing and no shoes. BMI (kilograms
per square meter) and waist to hip ratio were used as estimates of overall
and central adiposity. Systolic blood pressure was measured twice in
seated resting subjects using the Hypertension Detection and Follow–up
Program protocol (15); the mean of two readings was used in analyses.
Weight change, an indicator of health status, was determined by sub-
tracting the participant’s weight at the 1984–1987 visit from that ob-
tained at a 1972–1974 visit (99% of participants).
Blood samples were obtained by venipuncture between 0730 and
1100 h after a requested 12-h fast; serum and plasma were separated and
frozen at 70 C until first thawed for sex hormone assays in 1992–1994.
Hormone levels were measured in the University of California, San Di-
ego, endocrinology research laboratory of S. S. C. Yen. Total testoster-
one and estradiol levels were measured by RIA after solvent extraction
and celite column chromatography; procedural losses were monitored by
addition of tritiated standard to each sample before the extraction step.
Bioavailable testosterone and estradiol (the non-SHBG bound fractions)
were measured by an adaptation of the Tremblay and Dube ammonium-
sulfate precipitation method (16). In 2000, plasma C-reactive protein
(CRP) and IL-6 were measured on a subset of 614 participants in a
university laboratory by an automated, high-sensitivity method (N Latex
CRP mono; Dade Behring, Deerfield, IL; sensitivity: 0.2 mg/liter) and a
high sensitivity (0.094 pg/ml) ELISA with an alkaline phosphatase signal
amplification system (Quantikine HS, human IL-6 immunoassay; R&D
Systems, Minneapolis, MN), respectively. In 2004 adiponectin and lep-
tin levels were measured by RIA on twice-thawed serum samples at Linco
Diagnostics Laboratory (St. Louis, MO). The sensitivity and intra- and
interassay coefficients of variation, respectively, were 3 pg/ml and 6 and
7% for estradiol; 3 pg/ml  percentage free and 6 and 8% for bioavail-
able estradiol; 20 pg/ml and 4 and 5% for testosterone; 20 pg/ml 
percentage free and 7%, and 11% for bioavailable testosterone; 08
mg/liter and 6% and 7% for adiponectin; and 05 ng/ml and 4% and 5%
for leptin. Adiponectin, leptin and sex hormone levels did not vary by
years of frozen sample storage.
Fasting plasma total, high-density lipoprotein (HDL), low-density
lipoprotein (LDL) cholesterol, and triglyceride levels were measured in
a Centers for Disease Control and Prevention Certified Lipid Research
Clinic Laboratory. Total cholesterol and triglyceride levels were mea-
sured by enzymatic techniques using an ABA-200 biochromatic analyzer
(Abbott Laboratories, Irving, TX). HDL was measured after precipita-
tion of the other lipoproteins with heparin and manganese chloride. LDL
was estimated using the Friedewald formula (17). Plasma glucose levels
were measured by the glucose oxidase method, plasma insulin by double-
antibody RIA, and serum creatinine by the Jaffe reaction method. Ho-
meostasis model assessment for insulin resistance (HOMA-IR) was used
to estimate insulin resistance according to the formula: insulin (milliunits
per liter)  glucose (millimoles per liter)]/22.5.
Prevalent conditions and mortality assessment
Information on diabetes and cardiovascular disease (CVD) history
was obtained using standard interview questionnaires. Prevalent CVD
included angina [by physician diagnosis, Rose questionnaire (18), or
angina medication use], doctor-diagnosed myocardial infarction, car-
diac revascularization, congestive heart failure, stroke or transient isch-
emic attack, carotid surgery, peripheral arterial surgery, or physician-
diagnosed intermittent claudication. Diabetes was defined by physician
diagnosis, fasting plasma glucose 7.0 mmol/liter or greater (126 mg/dl),
2-h postchallenge glucose 11.1 mmol/liter or greater (200 mg/dl), or use
of diabetes medication (19). The metabolic syndrome was defined using
2002 National Cholesterol Education Program Adult Treatment Panel
III criteria (20). Hypertension was defined as blood pressure 130/85 mm
Hg or greater or use of antihypertensive medication.
Participants were followed through July 2004 by annual mailers and
periodic clinic visits. Vital status was known for 98% of participants. Death
certificates, obtained for 92% of decedents, were classified for underlying
causeofdeathbyacertifiednosologistusing the InternationalClassification
of Diseases, Ninth Revision. CVD deaths included codes 401–448, cancer
deaths codes 140–208, and respiratory disease deaths codes 460–519.
Statistical analysis
Sex hormone, HDL cholesterol, triglycerides, HOMA-IR, IL-6, CRP,
leptin, and adiponectin levels were not normally distributed and were
natural log transformed for analyses; reported values are geometric
means and interquartile ranges. The age-adjusted association of testos-
terone with baseline characteristics was assessed by partial Pearson cor-
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relations for continuous variables and comparing testosterone levels for
those with and without each dichotomous characteristic using ANOVA.
The association between baseline testosterone levels and all-cause
mortality was determined using Cox proportional hazards regressions;
goodness of fit was confirmed by the method by May and Hosmer (21).
Total and bioavailable testosterone levels were examined as quartiles
based on the entire population and as dichotomous variables comparing
the lowest quartile to all higher. Total testosterone was further examined
as deciles to determine the optimal level. Three separate regression mod-
els were evaluated in mortality analyses: the first adjusted for age, the
second added adjustment for BMI and waist to hip ratio, the third added
adjustment for lifestyle factors including physical activity (3 times per
week, yes/no), alcohol use (1 drinks/d vs. less or none), and current
smoking habit (yes/no). Secondary models added adjustment for testos-
terone covariates and potential biological mediators. There was no mul-
ticollinearity between independent variables in these models, and no
significant interactions were found. The proportional odds assumption,
assessed visually using log minus log plots, was met by all models.
All P presented are two tailed; P  0.05 was considered statistically
significant. Data were analyzed using SAS (version 9.1; SAS Institute,
Cary, NC) and SPSS (version 15.0; SPSS Inc., Chicago, IL).
Results
Baseline characteristics are shown in Tables 1 and 2. The median
age of these 794 men was 73.8 yr (range 50–91), 10% had a BMI
greater than 30 kg/m2, and 15% met Adult Treatment Panel III
criteria for central obesity (waist girth  102 cm). Only 11%
reported current smoking, half consumed at least one alcohol
drink daily, and 84% reported exercising three or more times per
week. The median total testosterone level was 300 ng/dl, and
27% of values were below the lower limit (246 ng/dl) of the
reference range for young men for the assay used in this study.
The median bioavailable testosterone level was 96 ng/dl (no ref-
erence range is available).
Testosterone and baseline characteristics
The associations of testosterone levels with baseline charac-
teristics, lifestyle variables, health status markers, and prevalent
conditions are presented in Tables 1 and 2. In these elderly men,




range Total T Ra BioT Ra
Age, yr 71.2 63.6–78.9 0.06 0.46b
Anthropomorphic parameters
Weight, kg 78.0 70.3–84.8 0.28b 0.11c
BMI, kg/m2 25.7 23.5–27.4 0.28b 0.07d
Waist to hip ratio 0.91 0.88–0.94 0.20b 0.05
Cardiovascular risk factors
Heart rate 60.9 54–67 0.04 0.03
SBP, mm Hg 139.7 126–151 0.11c 0.02
DBP, mm Hg 78.2 72–84 0.13b 0.01
Fasting glucose, mg/dle 102.1 93–109 0.14c 0.02
Fasting insulin, mIU/mle,f 12.0 8.2–16.0 0.25b 0.10d
HOMA-IRe,f,g 2.97 2.1–4.2 0.27b 0.09d
Cholesterol, mg/dl
Total 210.5 186–235 0.01 0.05
LDL 133.1 111–155 0.07 0.09d
HDLe 51.2 43–60 0.23b 0.03
Triglycerides, mg/dle 105.6 71–148 0.35b 0.04
Biomarkers
CRP, mg/litere,h 1.78 0.9–3.4 0.21b 0.12c
IL-6, mg/litere,h 2.63 1.7–3.9 0.14c 0.13c
Adiponectin, mg/litere 9.72 6.8–14.6 0.29b 0.01
Leptin, g/litere 6.22 4.1–9.0 0.32b 0.10c
Serum creatinine, mg/dle 1.22 1.1–1.4 0.04 0.03
Sex hormones
Testosterone, ng/dle 300 242–371 0.53b
Biotestosterone, pg/mle 94 78–116 0.53b
Estradiol, pg/mle 19 16–24 0.50b 0.35b
Bioestradiol, pg/mle 12 10–16 0.25b 0.52b
SBP, Systolic blood pressure; DBP, diastolic blood pressure.
a R is the age-adjusted partial correlation coefficient for each characteristic vs. log-transformed total and bioavailable testosterone levels.
b P  0.001.
c P  0.01.
d P  0.05.
e Values are geometric means, correlations based on log-transformed variables.
f Available on a subset of 556 men.
g HOMA-IR.
h Available on a subset of 614 men.
70 Laughlin et al. Testosterone and Mortality in Older Men J Clin Endocrinol Metab, January 2008, 93(1):68–75
bioavailable, but not total, testosterone levels were inversely re-
lated to age. However, after adjusting for age, total testosterone
levels were associated with more risk factors than bioavailable
testosterone and the association was generally stronger. Total
testosterone was inversely associated with weight, BMI, waist to
hip ratio, systolic and diastolic blood pressure, fasting plasma
glucose and serum insulin, HOMA-IR, triglycerides, CRP and
leptin levels and positively related to HDL cholesterol and adi-
ponectin levels (all P  0.01).
Total testosterone did not differ by smoking habit or exercise
but was slightly lower among men who consumed at least one
alcohol drink daily, compared with those who drank less or not
at all (P  0.05). Levels of total testosterone were higher in men
who had lost 10 or more pounds in the past 10 yr (P  0.05) and
lower in men who had gained at least 10 pounds (P  0.001),
those who reported two or more visits to the doctor in the past
year (P  0.05), and men who were taking two or more medi-
cations (P  0.05). Total testosterone did not differ significantly
for men with or without CVD or diabetes but was 8% lower for
men who had hypertension and 22% lower for men who had the
metabolic syndrome, compared with those who did not (both
P  0.001). Bioavailable testosterone levels were modestly lower
in men who had lost weight (P  0.05) but did not differ by other
categorical variables.
Testosterone and mortality
During an average 11.8-yr follow-up, 538 deaths occurred, a
mortality rate of 57.5 per 1000 person-years. In age-adjusted
analyses, the risk of death was significantly elevated for men in
the lowest quartile of the total and bioavailable testosterone dis-











Q4 (370) 436 1.0 (ref) 1.0 (ref) 1.0 (ref)
Q3 (300–370) 331 0.90 (0.71, 1.15) 0.95 (0.74, 1.21) 0.93 (0.73, 1.19)
Q2 (241–299) 273 1.04 (0.82, 1.32) 1.14 (0.89, 1.45) 1.15 (0.90, 1.47)
Q1 (241) 204 1.29 (1.02, 1.64) 1.42 (1.11, 1.82) 1.44 (1.12, 1.84)
PTREND 0.026 0.003 0.002
Bioavailable T (ng/dl)
Q4 (117) 135 1.0 (ref) 1.0 (ref) 1.0 (ref)
Q3 (96–117) 105 0.93 (0.71, 1.22) 0.96 (0.73, 1.27) 0.94 (0.72, 1.24)
Q2 (78–95) 87 1.11 (0.85, 1.44) 1.17 (0.89, 1.53) 1.16 (0.89, 1.52)
Q1 (78) 65 1.46 (1.12, 1.89) 1.52 (1.17, 1.99) 1.50 (1.15, 1.96)
PTREND 0.001 0.001 0.001
Ref, Reference category.
a Model 1, adjusted for age.
b Model 2, adjusted for age, BMI, and waist to hip ratio.
c Model 3, model 2  alcohol use, current smoking, and exercise.
TABLE 2. Age-adjusted total and bioavailable testosterone levels in men with and without selected lifestyle variables, health









Current smoking 11 316 / 296 96 / 94
Alcohol use, 1 drinks/d 51 291 / 306a 94 / 93
Exercise, 3 times/wk 85 299 / 294 95 / 91
Health status markers
10-yr weight loss  10 lb 23 311 / 294a 90 / 95a
10-yr weight gain  10 lb 17 262 / 306b 91 / 95
Two or more doctor visits in past year 69 292 / 311a 93 / 96
Two or more current medications 31 287 / 303a 93 / 94
Prevalent conditions
Hypertension 75 292 / 317b 94 / 93
Metabolic syndrome 18 244 / 311c 90 / 95
Diabetes 15 284 / 300 95 / 94
CVD 35 298 / 302 93 / 95
Values are geometric means, analyses based on log-transformed testosterone levels. T, Testosterone; BioT, bioavailable T.
a P  0.05.
b P  0.01.
c P  0.001.
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tributions, compared with those in the highest quartiles, but did
not differ significantly for men in the second and third quartiles
(Table 3). In a model adjusting for age, adiposity, and lifestyle
choices, the risk of death was 44% higher [hazards ratio (HR)
1.44, 95% confidence interval (CI) 1.12, 1.84)] for men in the
lowest quartile of total testosterone relative to the highest, with
similar results for bioavailable testosterone (HR 1.50, 95% CI
1.15, 1.96) (Table 3).
Examination of the association of total testosterone with all-
cause mortality by testosterone decile indicated that for men with
levels below the median (300 ng/dl), progressively lower levels were
associated with a step-wise increase in the risk of death and that
there was no additional survival benefit for men in the four highest
testosterone deciles, compared with those with midrange levels
(Fig. 1).
The influence of testosterone covariates and potential
biological mediators was examined by adding variables one by
one and in combination to the basic model (age, adiposity, and
lifestyle adjusted) and comparing men in the lowest testoster-
one quartile with those with higher values (Table 4). The
strength of the associations of low total and low bioavailable
testosterone with increased mortality risk was essentially
unchanged after additional adjustment for prevalent diabetes,
CVD, or the metabolic syndrome or by exclusion of those with
these conditions. Addition of a combination of health status
markers, HOMA-IR or adiponectin and leptin, also failed to
influence results, as did adjustment for estradiol or bioavail-
able estradiol levels. Adjustment for the inflammatory mark-
ers IL-6 and CRP attenuated the mortality association with
low testosterone levels using either total or bioavailable mea-
sures. In analyses stratified by CRP level, the HR (95% CI) for
low total testosterone was 0.78 (0.52, 1.15) for the 174 men
(n  125 deaths) with CRP 3 mg/dl or greater and 1.66 (1.23,







FIG. 1. All-cause mortality according to deciles of total testosterone
adjusting for age, BMI, waist to hip ratio, current smoking, alcohol use,
and exercise. The squares represent point estimates for HRs, the lines
indicate 95% CIs. The median total testosterone values for deciles 1–10
were 171, 209, 241, 266, 288, 314, 338, 370, 422, and 507 ng/dl,
respectively.
TABLE 4. HRs of low total testosterone and low bioavailable testosterone for all-cause mortality adjusting for (or excluding)





Lowest quartile vs. highera 1.40 (1.14, 1.71) 1.44 (1.19, 1.74)
Plus hypertensionb 1.39 (1.14, 1.70) 1.45 (1.19, 1.75)
Plus diabetes 1.37 (1.12, 1.69) 1.47 (1.21, 1.79)
Plus CVD 1.35 (1.11, 1.64) 1.44 (1.19, 1.75)
Plus metabolic syndrome 1.30 (1.06, 1.61) 1.45 (1.19, 1.76)
Plus health status markersc 1.36 (1.10, 1.67) 1.57 (1.29, 1.92)
Plus HOMA-IRd 1.41 (1.08, 1.85) 1.61 (1.24, 2.10)
Plus adiponectin, leptin 1.43 (1.16, 1.77) 1.45 (1.20, 1.77)
Plus CRP, IL-6e 1.27 (0.96, 1.57) 1.23 (0.96, 1.58)
Plus estradiol 1.35 (1.08, 1.68) 1.40 (1.15, 1.70)
Plus bioavailable estradiol 1.34 (1.09, 1.66) 1.39 (1.12, 1.71)
Excluding prevalent:
Diabetes (n  116) 1.45 (1.15, 1.82) 1.34 (1.09, 1.66)
CVD (n  274) 1.39 (1.09, 1.77) 1.40 (1.12, 1.76)
Metabolic syndrome (n  140) 1.43 (1.12, 1.83) 1.32 (1.06, 1.64)
T, Testosterone; BioT, biotestosterone.
a Basic model: reference is 241 ng/dl or greater for total testosterone, 78 ng/dl or greater for bioavailable testosterone, adjusted for age, BMI, waist to hip ratio, alcohol
use, current smoking, and exercise.
b Covariates were added one at a time to the basic model.
c The 10-yr weight change, heart rate, number of doctor visits in the past year, number of current medications, and serum creatinine.
d HOMA-IR, available on a subset of 556 men: HR for low T  1.44 (95% CI 1.11, 1.87), HR for low BioT  1.60 (95% CI 1.23, 2.08) for this subset for the basic
model.
e CRP and IL-6 available on a subset of 614 men: HR for low T  1.37 (95% CI 1.08, 1.73), HR for low BioT  1.40 (95% CI 1.11, 1.77) for this subset for the basic
model.
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In age-, adiposity-, and lifestyle-adjusted analyses of cause-
specific mortality, low total and bioavailable testosterone
were each significantly associated with elevated 20-yr risk of
CVD mortality and death due to respiratory disease but not
with cancer death or death due to other causes (Table 5). The
association of low testosterone with all-cause, CVD, and re-
spiratory disease mortality remained significant after exclud-
ing deaths that occurred during the first 5 yr of follow-up.
Discussion
To our knowledge, this is the first prospective population-based
study to show that low serum testosterone is associated with
increased risk of death in older community-dwelling men. Men
with total testosterone levels below the 25th percentile for this
population (241 ng/dl) had 40% higher risk of death over the
following 20 yr, compared with men with higher endogenous
testosterone, independent of age, obesity, and lifestyle choices.
These results were similar for the bioavailable fraction of tes-
tosterone and were not explained by overall health status.
Testicular function is suppressed in many acute and chronic
illnesses, resulting in reduced serum testosterone (12). Low testos-
terone has been reported in type 2 diabetes, chronic obstructive
pulmonarydisease,alcoholic liverdisease,andchronicrenaldisease
(12). In addition, several cohort studies (22), including this one,
have observed lower testosterone in men with the metabolic syn-
drome, and as many as one in four men with coronary heart disease
has testosterone levels in the hypogonadal range (23). Low testos-
terone could be a marker of preexisting disease and not an inde-
pendent risk factor for death. However, exclusion of men with di-
abetes, the metabolic syndrome, or cardiovascular disease had
negligibleeffectontheassociationof lowtestosteronewithall-cause
mortality in this study. Furthermore, the risk estimates for total
testosterone were stronger for cardiovascular and respiratory
deaths when deaths that occurred during the first 5 yr of follow-up
were excluded, suggesting that the testosterone-mortality associa-
tion is not explained by concurrent disease, whether known or
hidden.
Research suggests a role for metabolic effects of androgen defi-
ciency in the link between low testosterone and mortality. We, and
others, have shown that low testosterone precedes the development
of central obesity (24, 25), the metabolic syndrome (26, 27), and
diabetes (6, 27, 28) over the following 10–15 yr in nonobese men
without these conditions at baseline. In this study, lower total tes-
tosterone levelswereassociatedwithcentralobesityandestablished
CVD risk factors including insulin and insulin resistance, glycemia,
lipidprofile,andbloodpressureaswellasemergingriskfactorssuch
as leptin, adiponectin, IL-6, and CRP. In intervention studies, tes-
tosterone therapy improves, and testosterone ablation worsens,
central obesity and many of these biomarkers (29), evidence for a
causal association. Adjustment for most of these factors had min-
imal effect on the association of low testosterone with increased
mortality. Although a subset analysis suggested some mediation by
inflammatory processes, low testosterone was not associated with
mortality in men with elevated levels of CRP. Nonetheless, the
strong association of androgen deficiency with central obesity and
obesity-related factors remains a plausible pathway through which
testosterone influences the development of disease and subsequent
mortality.
These results differ from those in other prospective studies of
testosterone and mortality in relatively healthy community-dwell-
ingmen.Testosterone levelswerenotassociatedwithall-causemor-
tality in either the Caerphilly Study (13) of 2512 men or the Mas-
sachusettsMaleAgingStudy (MMAS) (14)of1686men.Themean
duration of follow-up in those studies (16.5 and 15.3 yr, respec-
tively)was somewhat longer thanours (12.4yr), but theproportion
dying was much lower (19 and 31%, respectively, vs. 68% for
Rancho Bernardo men), reflecting the almost 20 yr older average
age of men in the Rancho Bernardo Study. The absent association
in the earlier studies may reflect other population differences or
hormone assay differences, or the importance of low testosterone
for survival may become increasingly important as men age.
The observed low testosterone-mortality association was not
TABLE 5. HRs of low total testosterone and low bioavailable testosterone for cause-specific mortality by years of follow-up
Cause of death
0–20 yr follow-up 5–20 yr follow-up
n HR (95% CI) n HR (95% CI)
Low total testosteronea
All-cause 529 1.38 (1.12, 1.69) 409 1.60 (1.27, 2.02)
CVD 264 1.38 (1.02, 1.85) 199 1.73 (1.23, 2.45)
Cancer 127 1.34 (0.89, 2.00) 90 1.22 (0.75, 1.99)
Respiratory disease 54 2.29 (1.25, 4.20) 46 2.67 (1.37, 5.20)
Other 96 1.13 (0.68, 1.88) 83 1.51 (0.89, 2.56)
Low biotestosteroneb
All-cause 529 1.44 (1.19, 1.74) 409 1.44 (1.16, 1.80)
CVD 264 1.36 (1.04, 1.79) 199 1.39 (1.01, 1.92)
Cancer 127 1.50 (0.99, 2.26) 90 1.38 (0.82, 2.31)
Respiratory disease 54 1.84 (1.03, 3.28) 46 1.65 (0.86, 3.14)
Other 96 1.43 (0.91, 2.24) 83 1.56 (0.96, 2.53)
Adjusted for age, BMI, waist to hip ratio, alcohol use, current smoking, and exercise.
a Reference is total testosterone 241 ng/dl or greater.
b Reference is bioavailable testosterone 78 ng/dl or greater.
J Clin Endocrinol Metab, January 2008, 93(1):68–75 jcem.endojournals.org 73
specific to a single etiology. After excluding the first 5 yr of fol-
low-up (tominimize reverse causalitybycomorbidity), testosterone
was strongly associated with deaths due to cardiovascular and re-
spiratory disease. An association of low testosterone with respira-
tory disease mortality was also reported by the MMAS (14). Unlike
thepresent study, theassociation inMMASwasobservedonlywith
calculated free testosterone and not with total testosterone. In Ran-
cho Bernardo, measured bioavailable testosterone, which includes
both the albumin-bound and free testosterone fractions, was sig-
nificantly associated with respiratory disease death as well as with
all-cause mortality; free testosterone was not assayed.
The prevalence of hypogonadism in male populations is not
known with certainty, in part due to a lack of consensus on the
threshold that should be used to define testosterone insufficiency.
Some investigators recommend a total testosterone less than 300
ng/dl; others advocate cut points of 250 or even 200 ng/dl (29). The
median testosterone level for the present study (300 ng/dl) was
lower than that reported for two population-based cohorts of men
of similar age: the Osteoporotic Fractures in Men study of men 65
yroldandolderreportedameantotal testosterone levelof423ng/dl
(30), and the Health in Men study of men aged 70 yr and older
reported a mean of 444 ng/dl (31). Lower testosterone levels in our
study are likely due to differences in assay methods: both the Os-
teoporotic Fractures in Men and Health in Men studies measured
testosterone using direct assays, whereas the RIA used in this study
was preceded by two purification steps (organic solvent extraction
and celite column chromatography), minimizing cross-reactivity
with interfering substances (32).
Based on the lower overall mean testosterone, it could be argued
that our cut point of 241 ng/dl was too high and overestimates the
prevalence of low testosterone. Nonetheless, the 25% of men with
values below this threshold were at a 40% increased risk of death
over the following 20 yr, suggesting that a sizable proportion of
older community-dwelling men may have clinically significant tes-
tosterone insufficiency. Inasensitivityanalysis, loweringthe thresh-
old to 200 ng/dl reduced the proportion of men with low testos-
terone to 12% and increased the excess mortality risk to 45% (P 
0.007). It should be noted that use of these thresholds is arbitrary.
There is no current consensus on what constitutes a testosterone
insufficient state in older men, or indeed, if one even exists.
There is ongoing debate over the risk-benefit potential of tes-
tosterone therapy for men who are not clearly hypogonadal (33,
34). Results of the present study suggest that raising circulating
testosterone levels above 300 ng/dl (the median for this population)
offers no additional benefit, at least in terms of survival. This, plus
the limited availability of information on safety of testosterone re-
placement, argues against a recommendation for testosterone sup-
plementation to offset effects of male aging in men without docu-
mented androgen deficiency.
The present study has some limitations. Results were based on
an almost entirely Caucasian middle- to upper-middle-class com-
munity and may not apply to other ethnic and socioeconomic
groups. Repeat sampling of men with an initially low testosterone
level is recommended to confirm androgen deficiency (35), but this
and other epidemiological studies were based on a single measure-
ment of testosterone. However, misclassification of men with low
testosterone would be expected to underestimate, not cause, asso-
ciations. In addition, blood for testosterone samples was obtained
in the morning from fasting men, minimizing any diurnal variation
still present in this age group, and sampling at a single time point
fairly reliably reflects mean annual testosterone levels for older men
(36). Although it is possible that testosterone exerts its benefit by
conversion to estradiol, the addition of estradiol to these analyses
did not materially change the results, and estradiol was less strongly
associated with CVD risk factors than testosterone (data not
shown).
In summary, in this cohort, older men with low levels of cir-
culating total testosterone had a 40% increased risk of death over
the following 20 yr, compared with men with normal testoster-
one, independent of age, adiposity, and lifestyle. This association
was not explained by preexisting disease and was not specific to
a single cause of death. Testosterone levels above the median for
this population did not confer any additional survival benefit,
offering no support for widespread testosterone therapy for ag-
ing men. Randomized, placebo-controlled trials are necessary to
determine whether physiological testosterone replacement can
safely extend the quality and duration of life for older men with
well-documented testosterone insufficiency.
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